Ardea to Present Data on Inflammation Programs at 2008 Annual European Congress of Rheumatology
SAN DIEGO, June 5, 2008 /PRNewswire-FirstCall/ -- Ardea Biosciences, Inc. today announced that data will be presented on the Company's lead mitogen-activated ERK kinase (MEK) inhibitor, RDEA119, in the treatment of arthritis and on RDEA806 and RDEA594 in the treatment of gout at the 2008 Annual European Congress of Rheumatology Organized by the European League Against Rheumatism (EULAR) in Paris, France.
The presentation details are as follows: Date/Time: Thursday, June 12, 2008 from 11:45 a.m. - 1:30 p.m. CET Title: RDEA119, A Selective MEK1/2 Inhibitor Ameliorates Experimental Arthritis Location: Le Palais de Congres de Paris - Level 1 (Poster # THU0048) Date/Time: Thursday, June 12, 2008 from 11:45 a.m. - 1:30 p.m. CET Title: Safety and Uric Acid Lowering Effect in Humans Following Multiple Doses of RDEA806, A Novel Prodrug for the Potential Treatment of Hyperuricemia Location: Le Palais de Congres de Paris - Level 1 (Poster # THU0356) Date/Time: Thursday, June 12, 2008 from 11:45 a.m. - 1:30 p.m. CET Title: Mode of Action of RDEA594 as a Uric Acid Lowering Agent in Humans Following Multiple Doses of its Prodrug, RDEA806 Location: Le Palais de Congres de Paris - Level 1 (Poster # THU0357)
About Ardea Biosciences
Ardea Biosciences, Inc., of San Diego, California, is a biotechnology company focused on the discovery and development of small-molecule therapeutics for the treatment of HIV, cancer and inflammatory diseases, including gout. We have four drug candidates in clinical trials and others in preclinical development and discovery. Our most advanced development candidate is RDEA806, a non-nucleoside reverse transcriptase inhibitor (NNRTI), which is in a Phase 2a study for the treatment of HIV. We have evaluated our second- generation NNRTI for the treatment of HIV, RDEA427, in a human micro-dose pharmacokinetic study and have selected it as a development candidate. RDEA594, our lead development candidate for the treatment of gout, is in preclinical development and is believed to be an inhibitor of the URAT1 transporter in the kidney, which is responsible for regulation of uric acid levels. We are evaluating our lead MEK inhibitor, RDEA119, in a Phase 1 study in advanced cancer patients, as well as in a Phase 1 study in normal healthy volunteers as a precursor to trials in patients with inflammatory diseases. Lastly, we have evaluated our second-generation MEK inhibitor for the treatment of cancer and inflammatory diseases, RDEA436, in a human micro-dose pharmacokinetic study and have selected it as a development candidate.
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding our goals, including the expected properties and benefits of RDEA806, RDEA427, RDEA594, RDEA119, RDEA436 and our other compounds and the results of preclinical, clinical and other studies. Risks that contribute to the uncertain nature of the forward- looking statements include: risks related to the outcome of preclinical and clinical studies, risks related to regulatory approvals, delays in commencement of preclinical and clinical studies, and costs associated with our drug discovery and development programs and business development activities. These and other risks and uncertainties are described more fully in our most recently filed SEC documents, including our Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q, under the headings "Risk Factors." All forward-looking statements contained in this press release speak only as of the date on which they were made. We undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
CONTACT: Edie DeVine of WeissComm Partners, +1-415-946-1081, for ArdeaBiosciences, Inc.
Ticker Symbol: (NASDAQ-NMS:RDEA)
Terms and conditions of use apply
Copyright © 2008 PR Newswire Association LLC. All rights reserved.
A United Business Media Company
Posted: June 2008